Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Ist das der Durchbruch für den KI-Biotech-Geheimtipp?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFZT | ISIN: SE0020181014 | Ticker-Symbol: MVR0
Stuttgart
04.04.25
08:14 Uhr
0,106 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIVIR AB Chart 1 Jahr
5-Tage-Chart
MEDIVIR AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0890,13415:04

Aktuelle News zur MEDIVIR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.Medivir comments on the patent approval1
19.03.Medivir AB: Medivir receives European patent for fostrox plus lenvatinib in treatment of hepatocellular carcinoma (HCC) and cancer metastases in the liver83Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the...
► Artikel lesen
07.03.Medivir's CEO to "I am proud to see our research contribute to a global solution"1
25.02.Medivir AB: Medivir's partner Infex Therapeutics signs a license agreement for the clinical development of MET-X in India102Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that its...
► Artikel lesen
21.02.Medivir's investigator on the positive results directly from EASL1
19.02.Medivir Registered verzeichnet signifikanten Umsatzrückgang im letzten Quartal1
18.02.Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"1
MEDIVIR Aktie jetzt für 0€ handeln
18.02.Medivir AB: Year-End Report January - December 2024247"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinancial...
► Artikel lesen
23.12.24Medivir to highlight promising clinical data at EASL4
16.12.24Medivir's CEO to "The IND approval is a very important milestone"2
29.11.24Medivir's phase Ib/IIa study successfully concluded3
11.11.24Medivir's CEO: "There is an obvious need for fostrox"1
06.11.24Medivir AB: Interim Report January - September 202439"The improved results presented at ESMO and the collaboration agreement with Eisai have strengthened fostrox's chances of becoming the first approved therapy in second-line liver cancer". July - SeptemberFinancial...
► Artikel lesen
04.11.24Medivir signs new clinical trial collaboration with Eisai3
25.10.24Medivir's CEO to "Fostrox is unique in its kind"1
22.08.24Medivir AB: Interim Report January - June 2024197"Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer" STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- April - June Financial summary for the quarter Net...
► Artikel lesen
19.06.24Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility200STOCKHOLM, June 19, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
► Artikel lesen
23.05.24Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program249STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
30.04.24Medivir AB: Interim Report January - March 2024207"Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima...
► Artikel lesen
25.04.24Medivir AB: FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease361STOCKHOLM, April 25, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1